TOP > 外国特許検索 > SCREENING METHOD FOR SINGLE-CHAIN ANTIBODIES, AND SINGLE-CHAIN ANTIBODIES

SCREENING METHOD FOR SINGLE-CHAIN ANTIBODIES, AND SINGLE-CHAIN ANTIBODIES

外国特許コード F170009103
整理番号 (S2016-0105-N0)
掲載日 2017年6月14日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP082988
国際公開番号 WO 2017082214
国際出願日 平成28年11月7日(2016.11.7)
国際公開日 平成29年5月18日(2017.5.18)
優先権データ
  • 特願2015-219765 (2015.11.9) JP
  • 特願2016-024016 (2016.2.10) JP
発明の名称 (英語) SCREENING METHOD FOR SINGLE-CHAIN ANTIBODIES, AND SINGLE-CHAIN ANTIBODIES
発明の概要(英語) The present invention addresses the problem of providing: a screening method for single-chain antibodies having an extremely large capacity to bind with antigens, said method having excellent separation efficiency; and single-chain antibodies obtained using said screening method. This problem is solved by a screening method for single-chain antibodies that bind to antigens, said method comprising a step in which antigens bound to multilamellar liposomes are prepared, a step in which a phage library that displays single-chain antibodies is prepared, and a step in which phages displaying single-chain antibodies that bind to the antigens bound to the multilamellar liposomes are selected from the phage library.
特許請求の範囲(英語) [claim1]
1. The process which prepares the antigen which is connected to the multiplex membrane liposome,
The process which prepares the bacteriophage library which presents the single chain antibody, and
From the aforementioned bacteriophage library, the process which selects the bacteriophage which presents the single chain antibody which is connected to the antigen which is connected to the aforementioned multiplex membrane liposome
Screening method of the single chain antibody which it includes, connects to the antigen.
[claim2]
2. The aforementioned single chain antibody the 1.5x10 (- 2) s (- 1) it possesses the dissociation velocity factor below vis-a-vis the aforementioned antigen, in claim 1 method of statement.
[claim3]
3. The aforementioned single chain antibody is rabbit origin, in claim 1 or 2 method of statement.
[claim4]
4. The aforementioned antigen is the protein, either of the claim 1-3 in 1 sections method of statement.
[claim5]
5. The aforementioned protein is the antibody, in claim 4 method of statement.
[claim6]
6. The aforementioned antibody is the human serum origin IgG poly clonal antibody or the human serum origin IgA poly clonal antibody, in claim 5 method of statement.
[claim7]
7. It is the single chain antibody which the aforementioned single chain antibody connects to the L chain of the human origin antibody, in claim 5 or 6 method of statement.
[claim8]
8. The aforementioned protein includes the ekusosomu origin protein, in claim 4 method of statement.
[claim9]
9. The aforementioned protein, Extracellular Domain of Sf9 cell stocks origin CD9 2 (EC2) only the part is the fusion protein of Fc domain of the human antibody, in claim 8 method of statement.
[claim10]
10. The aforementioned protein is the virus origin protein, in claim 4 method of statement.
[claim11]
11. The aforementioned virus origin protein is the influenza virus origin protein, in claim 10 method of statement.
[claim12]
12. The aforementioned influenza virus origin protein is the B type influenza virus origin protein, in claim 11 method of statement.
[claim13]
13. The aforementioned B type influenza virus origin protein is B type influenza virus origin Nucleotide-binding Protein, in claim 12 method of statement.
[claim14]
14. The aforementioned protein is the inflammation characteristic protein, in claim 4 method of statement.
[claim15]
15. The aforementioned inflammation characteristic protein is human origin inflammation characteristic protein C-reactive (CRP) Protein, in claim 14 method of statement.
[claim16]
16. Either of the claim 1-15 in 1 sections with the screening method of statement the screening the process which is done,
The screening the process which decides the amino acid arrangement of the single chain antibody which is done,
On the basis of the arrangement of the variable territory of the amino acid arrangement which is decided, the process which draws up the DNA arrangement which the antibody the cord/code is done, and
The process which makes the DNA arrangement reveal which was drawn up in the host cell
It includes, production method of the antibody.
[claim17]
17. The DNA arrangement which the antibody the cord/code is done in the claim 16 which the human conversion antibody the cord/code is done production method of statement.
[claim18]
18. Vis-a-vis the human serum origin IgG poly clonal antibody the 3.0x10 (- 8) the single chain antibody which possesses the dissociation constant of M or less.
[claim19]
19. Furthermore, it connects to the human serum origin IgA poly clonal antibody, in claim 18 the single chain antibody of statement.
[claim20]
20. Vis-a-vis the human serum origin IgA poly clonal antibody the 1.0x10 (- 3) s (- 1) the single chain antibody which possesses the dissociation velocity factor below.
[claim21]
21. Vis-a-vis the L chain of the human origin antibody the 1.0x10 (- 3) s (- 1) the single chain antibody which possesses the dissociation velocity factor below.
[claim22]
22. Vis-a-vis the protein which includes the ekusosomu origin protein the 8.0x10 (- 3) s (- 1) the single chain antibody which possesses the dissociation velocity factor below.
[claim23]
23. The aforementioned protein, Extracellular Domain of Sf9 cell stocks origin CD9 2 (EC2) only the part is the fusion protein of Fc domain of the human antibody, in claim 22 the single chain antibody of statement.
[claim24]
24. Vis-a-vis the virus origin protein the 1.0x10 (- 2) s (- 1) the single chain antibody which possesses the dissociation velocity factor below.
[claim25]
25. The aforementioned virus origin protein is the influenza virus origin protein, in claim 24 the single chain antibody of statement.
[claim26]
26. The aforementioned influenza virus origin protein is the B type influenza virus origin protein, in claim 25 the chain antibody of statement.
[claim27]
27. The aforementioned B type influenza virus origin protein is B type influenza virus origin Nucleotide-binding Protein, in claim 26 the single chain antibody of statement.
[claim28]
28. Vis-a-vis the inflammation characteristic protein the 1.0x10 (- 2) s (- 1) the single chain antibody which possesses the dissociation velocity factor below.
[claim29]
29. The aforementioned inflammation characteristic protein is C-reactive (CRP) Protein, in claim 28 the single chain antibody of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • Kyoto Institute of Technology
  • 発明者(英語)
  • KUMADA YOICHI
  • HASEGAWA YUYA
  • UCHIMURA SEIICHI
国際特許分類(IPC)
指定国 (WO201782214)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close